• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia
【24h】

Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia

机译：Rozrolimupab，用于原发性免疫性血小板减少症的一流重组单克隆抗体产品

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Over the last decade the field of medicine has dramatically changed with the introduction of biological therapies, among which monoclonal antibodies play a pivotal role in the management of many diseases. Rozrolimupab is the first of a new class of recombinant human monoclonal antibody mixtures, consisting of 25 genetically unique IgG1 antibodies, targeted against the RhD erythrocyte antigen. It is currently being investigated for its use in the treatment of primary immune thrombocytopenia. Areas covered: This article outlines the impetus for the development of rozrolimupab in the treatment of ITP. In addition, the literature regarding the development of rozrolimupab and the recent clinical trials involving this agent are also reviewed. Expert opinion: Although rozrolimupab is only in the very early phases of clinical development we believe that this agent represents a very interesting agent not only for its potential benefits in the management of ITP but potentially for the prevention of haemolytic disease of the foetus and newborn.
机译：简介：在过去的十年中，随着生物疗法的引入，医学领域发生了翻天覆地的变化，其中单克隆抗体在许多疾病的治疗中起着关键作用。 Rozrolimupab是一类新型的重组人单克隆抗体混合物中的第一个，该混合物由25种针对RhD红细胞抗原的遗传学独特的IgG1抗体组成。目前正在研究其在治疗原发性免疫性血小板减少症中的用途。涵盖的领域：本文概述了Rozrolimupab在ITP治疗中的发展动力。另外，还综述了有关罗兹罗帕布的发展的文献以及涉及该药的最新临床试验。专家意见：尽管rozrolimupab仅仅处于临床开发的早期阶段，但我们认为，该药物不仅代表了其在ITP管理方面的潜在益处，而且还潜在于预防胎儿和新生儿的溶血性疾病，因此是一种非常有趣的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号